Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    haematology and oncology

    Cancer cachexia (supportive care)

    Also known as: Cancer-associated cachexia, Cancer anorexia–cachexia syndrome, Cancer-related wasting, Malignancy-associated cachexia

    Cancer cachexia is a multifactorial syndrome characterised by progressive skeletal muscle depletion, often accompanied by weight loss and reduced oral intake, which nutrition alone may not fully reverse. Clinical assessment requires evaluating malignancy activity, treatment-related toxicity, reversible barriers to ingestion, physical function, and goals of care. Standard care necessitates a multidisciplinary approach involving oncology, dietetics, and palliative medicine. Traditional Chinese Medicine provides an adjunctive framework for symptom-focused supportive care, without claims to restore muscle mass or alter survival. The referenced study of 60 patients with colorectal cancer examined serum hepatocyte growth factor in relation to disease status and nutrition, rather than evaluating cachexia interventions. No evidence exists for the efficacy of acupuncture or herbal medicine in this context, and the patterns represent traditional clinical constructs rather than validated cachexia phenotypes.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Collaborate with an oncology dietitian to establish realistic nutritional and palliative goals, minimising psychological distress regarding dietary intake.
    • •Consume small, nutrient-dense meals; modify food textures as required to manage stomatitis or dysphagia.
    • •Maintain gentle mobility or supervised resistance training only as tolerated and approved by an oncologist or physiotherapist, particularly if bone metastases or falls risk are present.
    • •Track intake barriers, weight trends, and daily function without burdensome monitoring; report clinical deterioration to the medical team rather than commencing restrictive dietary regimens or unreviewed supplements.

    Cautions & Contraindications

    See sources
    • •Defer needling during suspected infection, clinical instability or significant treatment-related cytopenias until the oncology team has assessed safety. Use local oncology protocols rather than assuming a universal safe blood-count threshold. The supplied study does not establish these precautions or thresholds.[]
    • •Avoid needling through tumour, infected or broken skin, unhealed surgical sites, radiation-injured tissue, vascular access devices or lymphoedematous areas; assess anticoagulant use and altered sensation. These are procedural precautions, not outcomes evaluated in the supplied study.[]
    • •Do not start herbal formulas without oncology-pharmacist review of anticancer medicines, anticoagulants, renal and hepatic function, electrolyte status and pregnancy. Safety and efficacy of the listed formulas were not examined in the supplied study.[]

    When to reassess or seek care again

    See sources

    Set baseline goals for appetite and nausea ratings, eating tolerance, sleep, fatigue and a feasible daily activity. Review within 1–2 weeks, sooner with deterioration; monitor weight approximately weekly when useful, accounting for oedema or ascites. Escalate ongoing intake decline, worsening weakness or continued weight loss to oncology and dietetics. Stop or revise adjunctive treatment if adverse effects occur or no meaningful symptom benefit emerges after a short agreed trial. HGF measurement is not justified for routine adjunctive-care monitoring by the supplied study.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. British journal of cancer · 1998

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.